1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Exosome Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Exosome Therapy Market, by Therapy Modality
8.1.1. Autologous Exosome Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Patient-derived cell exosomes
8.1.2.1. Market Revenue and Forecast
8.1.3. Point-of-care or near-patient processing
8.1.3.1. Market Revenue and Forecast
8.1.4. Allogeneic Exosome Therapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Donor-derived standardized exosomes
8.1.5.1. Market Revenue and Forecast
8.1.6. Off-the-shelf exosome preparations
8.1.6.1. Market Revenue and Forecast
9.1. Exosome Therapy Market, by Treatment Setting
9.1.1. Hospital-based therapies
9.1.1.1. Market Revenue and Forecast
9.1.2. Specialty clinics
9.1.2.1. Market Revenue and Forecast
9.1.3. Orthopedic clinics
9.1.3.1. Market Revenue and Forecast
9.1.4. Neurology clinics
9.1.4.1. Market Revenue and Forecast
9.1.5. Oncology clinics
9.1.5.1. Market Revenue and Forecast
9.1.6. Ambulatory surgical centers
9.1.6.1. Market Revenue and Forecast
9.1.7. Wellness / aesthetic centers
9.1.7.1. Market Revenue and Forecast
10.1. Exosome Therapy Market, by Therapeutic Use Case
10.1.1. Regenerative therapies
10.1.1.1. Market Revenue and Forecast
10.1.2. Musculoskeletal repair
10.1.2.1. Market Revenue and Forecast
10.1.3. Wound healing
10.1.3.1. Market Revenue and Forecast
10.1.4. Anti-inflammatory therapies
10.1.4.1. Market Revenue and Forecast
10.1.5. Neurorestorative therapies
10.1.5.1. Market Revenue and Forecast
10.1.6. Cardiometabolic therapies
10.1.6.1. Market Revenue and Forecast
10.1.7. Aesthetic & cosmetic therapies
10.1.7.1. Market Revenue and Forecast
10.1.8. Skin rejuvenation
10.1.8.1. Market Revenue and Forecast
10.1.9. Hair restoration
10.1.9.1. Market Revenue and Forecast
10.1.10. Supportive/adjunctive therapies
10.1.10.1. Market Revenue and Forecast
11.1. Exosome Therapy Market, by Administration Approach
11.1.1. Systemic therapy
11.1.1.1. Market Revenue and Forecast
11.1.2. IV-based exosome therapy
11.1.2.1. Market Revenue and Forecast
11.1.3. Local therapy
11.1.3.1. Market Revenue and Forecast
11.1.4. Intra-articular
11.1.4.1. Market Revenue and Forecast
11.1.5. Intradermal
11.1.5.1. Market Revenue and Forecast
11.1.6. Intrathecal
11.1.6.1. Market Revenue and Forecast
11.1.7. Topical application
11.1.7.1. Market Revenue and Forecast
12.1. Exosome Therapy Market, by Exosome Source Type
12.1.1. Stem cell–derived exosomes
12.1.1.1. Market Revenue and Forecast
12.1.2. Immune cell–derived exosomes
12.1.2.1. Market Revenue and Forecast
12.1.3. Tissue-derived exosomes
12.1.3.1. Market Revenue and Forecast
12.1.4. Plant-derived exosomes
12.1.4.1. Market Revenue and Forecast
13.1. Exosome Therapy Market, by Regulatory Classification
13.1.1. Regulated therapeutic procedures
13.1.1.1. Market Revenue and Forecast
13.1.2. Compassionate-use / experimental therapies
13.1.2.1. Market Revenue and Forecast
13.1.3. Non-regulated / wellness-based therapies
13.1.3.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapy Modality
14.1.2. Market Revenue and Forecast, by Treatment Setting
14.1.3. Market Revenue and Forecast, by Therapeutic Use Case
14.1.4. Market Revenue and Forecast, by Administration Approach
14.1.5. Market Revenue and Forecast, by Exosome Source Type
14.1.6. Market Revenue and Forecast, by Regulatory Classification
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapy Modality
14.1.7.2. Market Revenue and Forecast, by Treatment Setting
14.1.7.3. Market Revenue and Forecast, by Therapeutic Use Case
14.1.7.4. Market Revenue and Forecast, by Administration Approach
14.1.8. Market Revenue and Forecast, by Exosome Source Type
14.1.8.1. Market Revenue and Forecast, by Regulatory Classification
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapy Modality
14.1.9.2. Market Revenue and Forecast, by Treatment Setting
14.1.9.3. Market Revenue and Forecast, by Therapeutic Use Case
14.1.9.4. Market Revenue and Forecast, by Administration Approach
14.1.10. Market Revenue and Forecast, by Exosome Source Type
14.1.11. Market Revenue and Forecast, by Regulatory Classification
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapy Modality
14.2.2. Market Revenue and Forecast, by Treatment Setting
14.2.3. Market Revenue and Forecast, by Therapeutic Use Case
14.2.4. Market Revenue and Forecast, by Administration Approach
14.2.5. Market Revenue and Forecast, by Exosome Source Type
14.2.6. Market Revenue and Forecast, by Regulatory Classification
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapy Modality
14.2.8.2. Market Revenue and Forecast, by Treatment Setting
14.2.8.3. Market Revenue and Forecast, by Therapeutic Use Case
14.2.9. Market Revenue and Forecast, by Administration Approach
14.2.10. Market Revenue and Forecast, by Exosome Source Type
14.2.10.1. Market Revenue and Forecast, by Regulatory Classification
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapy Modality
14.2.11.2. Market Revenue and Forecast, by Treatment Setting
14.2.11.3. Market Revenue and Forecast, by Therapeutic Use Case
14.2.12. Market Revenue and Forecast, by Administration Approach
14.2.13. Market Revenue and Forecast, by Exosome Source Type
14.2.14. Market Revenue and Forecast, by Regulatory Classification
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapy Modality
14.2.15.2. Market Revenue and Forecast, by Treatment Setting
14.2.15.3. Market Revenue and Forecast, by Therapeutic Use Case
14.2.15.4. Market Revenue and Forecast, by Administration Approach
14.2.16. Market Revenue and Forecast, by Exosome Source Type
14.2.16.1. Market Revenue and Forecast, by Regulatory Classification
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapy Modality
14.2.17.2. Market Revenue and Forecast, by Treatment Setting
14.2.17.3. Market Revenue and Forecast, by Therapeutic Use Case
14.2.17.4. Market Revenue and Forecast, by Administration Approach
14.2.18. Market Revenue and Forecast, by Exosome Source Type
14.2.18.1. Market Revenue and Forecast, by Regulatory Classification
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapy Modality
14.3.2. Market Revenue and Forecast, by Treatment Setting
14.3.3. Market Revenue and Forecast, by Therapeutic Use Case
14.3.4. Market Revenue and Forecast, by Administration Approach
14.3.5. Market Revenue and Forecast, by Exosome Source Type
14.3.6. Market Revenue and Forecast, by Regulatory Classification
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapy Modality
14.3.7.2. Market Revenue and Forecast, by Treatment Setting
14.3.7.3. Market Revenue and Forecast, by Therapeutic Use Case
14.3.7.4. Market Revenue and Forecast, by Administration Approach
14.3.8. Market Revenue and Forecast, by Exosome Source Type
14.3.9. Market Revenue and Forecast, by Regulatory Classification
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapy Modality
14.3.10.2. Market Revenue and Forecast, by Treatment Setting
14.3.10.3. Market Revenue and Forecast, by Therapeutic Use Case
14.3.10.4. Market Revenue and Forecast, by Administration Approach
14.3.11. Market Revenue and Forecast, by Exosome Source Type
14.3.11.1. Market Revenue and Forecast, by Regulatory Classification
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapy Modality
14.3.12.2. Market Revenue and Forecast, by Treatment Setting
14.3.12.3. Market Revenue and Forecast, by Therapeutic Use Case
14.3.12.4. Market Revenue and Forecast, by Administration Approach
14.3.12.5. Market Revenue and Forecast, by Exosome Source Type
14.3.12.6. Market Revenue and Forecast, by Regulatory Classification
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapy Modality
14.3.13.2. Market Revenue and Forecast, by Treatment Setting
14.3.13.3. Market Revenue and Forecast, by Therapeutic Use Case
14.3.13.4. Market Revenue and Forecast, by Administration Approach
14.3.13.5. Market Revenue and Forecast, by Exosome Source Type
14.3.13.6. Market Revenue and Forecast, by Regulatory Classification
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapy Modality
14.4.2. Market Revenue and Forecast, by Treatment Setting
14.4.3. Market Revenue and Forecast, by Therapeutic Use Case
14.4.4. Market Revenue and Forecast, by Administration Approach
14.4.5. Market Revenue and Forecast, by Exosome Source Type
14.4.6. Market Revenue and Forecast, by Regulatory Classification
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapy Modality
14.4.7.2. Market Revenue and Forecast, by Treatment Setting
14.4.7.3. Market Revenue and Forecast, by Therapeutic Use Case
14.4.7.4. Market Revenue and Forecast, by Administration Approach
14.4.8. Market Revenue and Forecast, by Exosome Source Type
14.4.9. Market Revenue and Forecast, by Regulatory Classification
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapy Modality
14.4.10.2. Market Revenue and Forecast, by Treatment Setting
14.4.10.3. Market Revenue and Forecast, by Therapeutic Use Case
14.4.10.4. Market Revenue and Forecast, by Administration Approach
14.4.11. Market Revenue and Forecast, by Exosome Source Type
14.4.12. Market Revenue and Forecast, by Regulatory Classification
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapy Modality
14.4.13.2. Market Revenue and Forecast, by Treatment Setting
14.4.13.3. Market Revenue and Forecast, by Therapeutic Use Case
14.4.13.4. Market Revenue and Forecast, by Administration Approach
14.4.13.5. Market Revenue and Forecast, by Exosome Source Type
14.4.13.6. Market Revenue and Forecast, by Regulatory Classification
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapy Modality
14.4.14.2. Market Revenue and Forecast, by Treatment Setting
14.4.14.3. Market Revenue and Forecast, by Therapeutic Use Case
14.4.14.4. Market Revenue and Forecast, by Administration Approach
14.4.14.5. Market Revenue and Forecast, by Exosome Source Type
14.4.14.6. Market Revenue and Forecast, by Regulatory Classification
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapy Modality
14.5.2. Market Revenue and Forecast, by Treatment Setting
14.5.3. Market Revenue and Forecast, by Therapeutic Use Case
14.5.4. Market Revenue and Forecast, by Administration Approach
14.5.5. Market Revenue and Forecast, by Exosome Source Type
14.5.6. Market Revenue and Forecast, by Regulatory Classification
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapy Modality
14.5.7.2. Market Revenue and Forecast, by Treatment Setting
14.5.7.3. Market Revenue and Forecast, by Therapeutic Use Case
14.5.7.4. Market Revenue and Forecast, by Administration Approach
14.5.8. Market Revenue and Forecast, by Exosome Source Type
14.5.8.1. Market Revenue and Forecast, by Regulatory Classification
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapy Modality
14.5.9.2. Market Revenue and Forecast, by Treatment Setting
14.5.9.3. Market Revenue and Forecast, by Therapeutic Use Case
14.5.9.4. Market Revenue and Forecast, by Administration Approach
14.5.9.5. Market Revenue and Forecast, by Exosome Source Type
14.5.9.6. Market Revenue and Forecast, by Regulatory Classification
15.1. Evox Therapeutics
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Codiak BioSciences
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. ExoCoBio
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. ILIAS Biologics
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Aruna Bio
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Capricor Therapeutics
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. EV Therapeutics
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Kimera Labs
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Aethlon Medical
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Coya Therapeutics
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
